Bavarian Nordic tanks after BMS-partnered vaccine flunks phase 3 by Nick Paul Taylor Friday, September 15, 2017 The data monitoring committee ended the trial after ruling it would be futile to keep treating patients with the BMS-partnered Prostvac.
Bavarian Nordic delays phase 3 cancer vaccine data again by Nick Paul Taylor Friday, June 16, 2017 Bavarian Nordic has again delayed the release of data from a phase 3 trial of Prostvac.
Buffeted by headwinds, Bavarian Nordic cancels IPO by Ben Adams Thursday, April 14, 2016 “Market conditions” strike again as cancer vaccine biotech Bavarian Nordic has dropped an $86 million IPO.
